You are viewing an incomplete version of our website. Please click to reload the website as full version.

Browse our anti-HRAS (HRAS) Antibodies

Full name:
anti-V-Ha-Ras Harvey Rat Sarcoma Viral Oncogene Homolog Antibodies (HRAS)
On are 138 V-Ha-Ras Harvey Rat Sarcoma Viral Oncogene Homolog (HRAS) Antibodies from 26 different suppliers available. Additionally we are shipping HRAS Proteins (20) and HRAS Kits (13) and many more products for this protein. A total of 180 HRAS products are currently listed.
AI929937, C-BAS/HAS, c-H-ras, c-Ha-ras, C-HA-RAS1, c-rasHa, CTLO, H-ras, H-RASIDX, Ha-ras, HAMSV, Harvey-ras, hras, Hras-1, HRAS1, K-ras, Ki-ras, Kras-2, Kras2, N-RAS, p21B, ras, RASH1, zgc:110250

Most Popular Reactivities for anti-HRAS (HRAS) Antibodies

Select your species and application

anti-Human HRAS Antibodies:

anti-Rat (Rattus) HRAS Antibodies:

anti-Mouse (Murine) HRAS Antibodies:

All available anti-HRAS Antibodies

Go to our pre-filtered search.

Top referenced anti-HRAS Antibodies

  1. Human Polyclonal HRAS Primary Antibody for EIA, IF - ABIN952792 : Ma, Liu, Wu, Terada: p66(Shc) restrains Ras hyperactivation and suppresses metastatic behavior. in Oncogene 2010 (PubMed)
    Show all 5 references for ABIN952792

  2. Human Monoclonal HRAS Primary Antibody for EIA, WB - ABIN238418 : Prior, Harding, Yan, Sluimer, Parton, Hancock: GTP-dependent segregation of H-ras from lipid rafts is required for biological activity. in Nature cell biology 2001 (PubMed)
    Show all 5 references for ABIN238418

  3. Human Polyclonal HRAS Primary Antibody for IF, WB - ABIN655622 : van Engen-van Grunsven, van Dijk, Ruiter, Klaasen, Mooi, Blokx: HRAS-mutated Spitz tumors: A subtype of Spitz tumors with distinct features. in The American journal of surgical pathology 2010 (PubMed)
    Show all 4 references for ABIN655622

  4. Human Polyclonal HRAS Primary Antibody for EIA, WB - ABIN360066 : Coats, Booden, Buss: Transient palmitoylation supports H-Ras membrane binding but only partial biological activity. in Biochemistry 1999 (PubMed)
    Show all 3 references for ABIN360066

  5. Human Polyclonal HRAS Primary Antibody for IF, IHC (p) - ABIN392183 : Maemoto, Yumoto, Ibata, Torizuka, Ozawa, Tatsumi, Hashido, Morikawa, Maeda, Imai: Mutational analysis of HRAS and KRAS genes in oral carcinoma cell lines. in Odontology / the Society of the Nippon Dental University 2012 (PubMed)
    Show all 2 references for ABIN392183

  6. Human Polyclonal HRAS Primary Antibody for ELISA, WB - ABIN561363 : Ambrosini, Khanin, Carvajal, Schwartz: Overexpression of DDX43 mediates MEK inhibitor resistance through RAS Upregulation in uveal melanoma cells. in Molecular cancer therapeutics 2014 (PubMed)

More Antibodies against HRAS Interaction Partners

Cow (Bovine) V-Ha-Ras Harvey Rat Sarcoma Viral Oncogene Homolog (HRAS) interaction partners

  1. Data demonstrate that H-Ras activation is important in the activation of the specific signaling events leading to the accelerated retinal capillary cell apoptosis in hyperglycemic conditions.

  2. Activation of H-Ras and its downstream signaling pathway in the retina and its vasculature could be under the control of superoxide, and H-Ras activation in diabetes can be prevented by inhibiting superoxide accumulation.

  3. Thrombospondin 1 (show THBS1 Antibodies), fibronectin (show FN1 Antibodies), and vitronectin (show VTN Antibodies) are differentially dependent upon RAS, ERK1/2 (show MAPK1/3 Antibodies), and p38 (show MAPK14 Antibodies) for induction of vascular smooth muscle cell chemotaxis.

Zebrafish V-Ha-Ras Harvey Rat Sarcoma Viral Oncogene Homolog (HRAS) interaction partners

  1. Kita driven expression of oncogenic HRAS leads to early onset and highly penetrant melanoma in zebrafish

Human V-Ha-Ras Harvey Rat Sarcoma Viral Oncogene Homolog (HRAS) interaction partners

  1. herefore, our results also demonstrate that the phenotype in CS and somatic cancers is not only determined by the different transforming potentials of mutant HRAS proteins, but also by the efficiency of exon 2 inclusion resulting from the different HRAS mutations.

  2. Point mutations of HRAS is associated with thyroid cancer.

  3. The results show that mutant RAS is associated with an earlier and higher rate of local tumour progression in patients undergoing ablation of CLMs.

  4. A report of three cases with pediatric urothelial bladder cancer indicates that the tumors are characterized by a consistent H-RAS mutation status, whereas FGFR3 (show FGFR3 Antibodies) and p53 (show TP53 Antibodies) pathways are not involved in this tumor initiation.

  5. The coexistence of BRAF (show BRAF Antibodies) or RAS mutations enhanced the prognostic effects of telomerase reverse transcriptase (TERT (show TERT Antibodies)) promoter mutations. Furthermore, TERT (show TERT Antibodies) promoter mutations strengthened the predictions of mortality and recurrence by the ATA and TNM (show ODZ1 Antibodies) staging systems, particularly for high-risk patients with differentiated thyroid cancer.

  6. Overexpression of HRAS is associated with Breast Cancer Recurrence.

  7. Study acts as a further supplement of the genetic features of neuroendocrine tumors. Somatic mutations of three potential tumor-related genes (HRAS, PAK1 (show PAK1 Antibodies) and MEN1 (show MEN1 Antibodies)) might contribute to the tumorigenesis of thymic neuroendocrine tumors with EAS.

  8. Activating HRAS, KRAS and EGFR (show EGFR Antibodies) mutations play a major role in the pathogenesis of sporadic SGH. These results support the concept that SGH is a true benign neoplasm rather than a reactive hyperplasia.

  9. HRAS mutation is associated with liver cancer.

  10. findings support a role of HRAS mutations as a somatic driver event in benign PPGL without other known susceptibility gene mutations. HRAS mutated PPGL cluster together with NF1 (show NF1 Antibodies)- and RET (show RET Antibodies)-mutated tumors associated with activation of kinase-signaling pathways

Mouse (Murine) V-Ha-Ras Harvey Rat Sarcoma Viral Oncogene Homolog (HRAS) interaction partners

  1. We establishment the transgenic mouse model of K-ras(G12D) p53 (show TP53 Antibodies)(loxP/loxP) and found that K-ras mutation and p53 (show TP53 Antibodies) deletion within the ovarian surface epithelium gave rise to ovarian lesions with a hyperproliferation and endometrioid glandular morphology

  2. K-Ras knockout (KO) mouse embryonic fibroblasts (K-ras(-/-) ) stimulated with transforming growth factor-beta1 (TGF-beta1 (show TGFB1 Antibodies)) exhibited reduced proliferation and impaired mobility than wild-type fibroblasts

  3. The abnormal expression of epidermal cytokeratins suggests that Ha-Ras and Bcl-2 (show BCL2 Antibodies) suppress the terminal differentiation and sustain the stem cell-like features in epidermal keratinocytes

  4. findings demonstrate that advanced gastric tumorigenesis requires oncogenic KRAS or BRAF (show BRAF Antibodies) in concert with aberrant STAT3 (show STAT3 Antibodies) activation in epithelial precursor cells of the glandular stomach

  5. Ras (G12V)-induced cyclin D1 (show CCND1 Antibodies) protein synthesis was markedly suppressed by the knockdown of IL-33 (show IL33 Antibodies).

  6. oncogenic KRas-induced increase in fluid-phase endocytosis has a key role during cellular transdifferentiation in pancreatic acinar cells. This result supports emerging evidence for endocytosis playing a crucial role in regulating the signaling output of the cells

  7. This study reveals KRAS(G12D) uniquely regulates tumor cells via heterotypic stromal cells. By exploiting heterocellularity, reciprocal signaling enables KRAS(G12D) to engage oncogenic signaling pathways beyond those regulated in a cell-autonomous manner.

  8. We also uncovered that Prox1-heterozygosis markedly increases the formation of acinar-to-ductal-metaplasias and early neoplasias, and enhances features associated with inflammation, in mouse pancreatic tissues expressing oncogenic Kras.

  9. The mutant KRas can initiate the transcription of the epidermal growth factor (show EGF Antibodies) receptors and its ligands by increasing mitochondrial generation of ROS (show ROS1 Antibodies) and activation of NF-kB signaling through protein kinase D1 (show PRKD1 Antibodies).

  10. Findings suggest that COX-2 (show COX2 Antibodies) deletion contributes to the repression of K-ras-induced lung tumorigenesis by reducing tumor cell proliferation, decreasing the production of PGE2, and increasing the production of 13,14-dihydro-15-keto-PGE2, possibly via the MAPK (show MAPK1 Antibodies) pathway.

HRAS Antigen Profile

Antigen Summary

This gene belongs to the Ras oncogene family, whose members are related to the transforming genes of mammalian sarcoma retroviruses. The products encoded by these genes function in signal transduction pathways. These proteins can bind GTP and GDP, and they have intrinsic GTPase activity. This protein undergoes a continuous cycle of de- and re-palmitoylation, which regulates its rapid exchange between the plasma membrane and the Golgi apparatus. Mutations in this gene cause Costello syndrome, a disease characterized by increased growth at the prenatal stage, growth deficiency at the postnatal stage, predisposition to tumor formation, mental retardation, skin and musculoskeletal abnormalities, distinctive facial appearance and cardiovascular abnormalities. Defects in this gene are implicated in a variety of cancers, including bladder cancer, follicular thyroid cancer, and oral squamous cell carcinoma. Multiple transcript variants, which encode different isoforms, have been identified for this gene.

Alternative names and synonyms associated with HRAS

  • Harvey rat sarcoma viral oncogene homolog (hras) antibody
  • v-Ha-ras Harvey rat sarcoma viral oncogene homolog (HRAS) antibody
  • v-Ha-ras Harvey rat sarcoma viral oncogene homolog a (hrasa) antibody
  • neuroblastoma RAS viral (v-ras) oncogene homolog (NRAS) antibody
  • v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS) antibody
  • Harvey rat sarcoma viral oncogene homolog (HRAS) antibody
  • Harvey rat sarcoma virus oncogene (Hras) antibody
  • Harvey rat sarcoma virus oncogene 1 (Hras1) antibody
  • v-Ha-ras Harvey rat sarcoma viral oncogene homolog (Hras) antibody
  • v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (Kras) antibody
  • AI929937 antibody
  • C-BAS/HAS antibody
  • c-H-ras antibody
  • c-Ha-ras antibody
  • C-HA-RAS1 antibody
  • c-rasHa antibody
  • CTLO antibody
  • H-ras antibody
  • H-RASIDX antibody
  • Ha-ras antibody
  • HAMSV antibody
  • Harvey-ras antibody
  • hras antibody
  • Hras-1 antibody
  • HRAS1 antibody
  • K-ras antibody
  • Ki-ras antibody
  • Kras-2 antibody
  • Kras2 antibody
  • N-RAS antibody
  • p21B antibody
  • ras antibody
  • RASH1 antibody
  • zgc:110250 antibody

Protein level used designations for HRAS

v-Ha-ras Harvey rat sarcoma viral oncogene homolog , small G-protein H-Ras , Harvey ras 1 , p19 H-RasIDX protein , GTPase HRas (Transforming protein p21) (H-Ras-1) (c-H-ras) , xRAS1 , GTPase HRas , Transforming protein p21 , neuroblastoma ras oncogene , GTP- and GDP-binding peptide B , H-Ras-1 , Ha-Ras1 proto-oncoprotein , Ras family small GTP binding protein H-Ras , c-has/bas p21 protein , c-ras-Ki-2 activated oncogene , p21ras , transformation gene: oncogene HAMSV , transforming protein p21 , Harvey ras1 protein , Harvey rat sarcoma viral (v-Ha-ras) oncogene homolog , H-ras 1 protein , c-Ha-ras p21 protein , c-Ha-ras transgene , transforming protein P21 , GTPase NRas , transforming protein N-Ras , c-H-ras , v-Ha-ras Harvey rat sarcoma viral oncogene-like protein , ras p21 , GTPase KRas , K-Ras 2 , Kirsten rat sarcoma oncogene 2, expressed , c-K-ras , c-Ki-ras , p21 protein

399406 Xenopus laevis
466302 Pan troglodytes
513012 Bos taurus
549757 Xenopus (Silurana) tropicalis
550286 Danio rerio
698830 Macaca mulatta
733587 Sus scrofa
100222058 Taeniopygia guttata
100227892 Taeniopygia guttata
3265 Homo sapiens
293621 Rattus norvegicus
15461 Mus musculus
100739349 Sus scrofa
100735038 Cavia porcellus
396229 Gallus gallus
403735 Canis lupus familiaris
100298939 Bos taurus
101104357 Ovis aries
16653 Mus musculus
Selected quality suppliers for anti-HRAS (HRAS) Antibodies
Did you look for something else?